Ankit Malik

Dr. Ankit Malik


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Cell
Verified
Journal Article
Closed access
SMSi Ming Man
Si Ming Man
QZQifan Zhu
Qifan Zhu
LZLiqin Zhu
Liqin Zhu
ZLZhiping Liu
Zhiping Liu
RKRajendra Karki
Rajendra Karki
Thirumala-Devi KannegantiThirumala-Devi Kanneganti
Thirumala-Devi Kanneganti

24 October 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AMAnkit Malik
Ankit Malik
DSDeepika Sharma
Deepika Sharma
QZQIFAN ZHU
QIFAN ZHU
RKRajendra Karki
Rajendra Karki
CGClifford S. Guy
Clifford S. Guy
Thirumala-Devi KannegantiThirumala-Devi Kanneganti
Thirumala-Devi Kanneganti
Inflammatory bowel diseases (IBD) affect over 5 million individuals in the industrialized world, with an increasing incidence rate worldwide. IBD also predisposes affected individuals to development of colorectal cancer, which is a leading cause of cancer-related deaths in adults. Mutations in genes encoding molecules in the IL-33 signaling pathway are associated with colitis and colitis-associated cancer (CAC), but how IL-33 modulates gut homeostasis is unclear. Here, we have shown that Il33-deficient mice are highly susceptible to colitis and CAC. Mechanistically, we observed that IL-33 promoted IgA production from B cells, which is important for maintaining microbial homeostasis in the intestine. Il33-deficient mice developed a dysbiotic microbiota that was characterized by increased levels of mucolytic and colitogenic bacteria. In response to chemically induced colitis, this microbial landscape promoted the release of IL-1α, which acted as a critical driver of colitis and CAC. Consequently, reconstitution of symbiotic microbiota or IL-1α ablation markedly ameliorated colitis susceptibility in Il33-deficient animals. Our results demonstrate that IL-33 promotes IgA production to maintain gut microbial homoeostasis and restrain IL-1α–dependent colitis and CAC. This study therefore highlights modulation of IL-33, IgA, IL-1α, and the microbiota as a potential therapeutic approach in the treatment of IBD and CAC.

1 June 2015 in Current Opinion in Virology
Verified
Journal Article
Closed access
CLChristopher Lupfer
Christopher Lupfer
AMAnkit Malik
Ankit Malik
Thirumala-Devi KannegantiThirumala-Devi Kanneganti
Thirumala-Devi Kanneganti

22 November 2023 in Nature
Verified
Journal Article
Closed access
PDF file
AMAnkit Malik
Ankit Malik
DSDeepika Sharma
Deepika Sharma
RARaúl Aguirre-Gamboa
Raúl Aguirre-Gamboa
SMShaina McGrath
Shaina McGrath
SZSarah Zabala
Sarah Zabala
BJBana Jabri
Bana Jabri

1 July 2014 in Mucosal Immunology
Verified
Journal Article
Open access
PDF file
AMAnkit Malik
Ankit Malik
DSD Sharma
D Sharma
JCJ St Charles
J St Charles
LDL A Dybas
L A Dybas
Linda S. MansfieldLinda S. Mansfield
Linda S. Mansfield
Campylobacter jejuni is a leading cause of foodborne enteritis that has been linked to the autoimmune neuropathy, Guillain Barré syndrome (GBS). C57BL/6 interleukin (IL)-10+/+ and congenic IL-10−/− mice serve as C. jejuni colonization and colitis models, respectively, but a mouse model for GBS is lacking. We demonstrate that IL-10−/− mice infected with a C. jejuni colitogenic human isolate had significantly upregulated type 1 and 17 but not type 2 cytokines in the colon coincident with infiltration of phagocytes, T cells and innate lymphoid cells (ILCs). Both ILC and T cells participated in interferon-γ (IFN-γ), IL-17, and IL-22 upregulation but in a time- and organ-specific manner. T cells were, however, necessary for colitis as mice depleted of Thy-1+ cells were protected while neither Rag1−/− nor IL-10R blocked Rag1−/− mice developed colitis after infection. Depleting IFN-γ, IL-17, or both significantly ameliorated colitis and drove colonic responses toward type 2 cytokine and antibody induction. In contrast, C. jejuni GBS patient strains induced mild colitis associated with blunted type 1/17 but enhanced type 2 responses. Moreover, the type 2 but not type 1/17 antibodies cross-reacted with peripheral nerve gangliosides demonstrating autoimmunity.

1 February 2017 in Journal of Autoimmunity
Verified
Journal Article
Closed access
JCJ.L. St Charles
J.L. St Charles
JBJ.A. Bell
J.A. Bell
BGB.J. Gadsden
B.J. Gadsden
AMAnkit Malik
Ankit Malik
HCH. Cooke
H. Cooke
Linda S. MansfieldLinda S. Mansfield
Linda S. Mansfield